High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor fidarestat: Stereospecific interaction between the enzyme and a cyclic imide type inhibitor

Journal of Medicinal Chemistry

Volumn 47, Issue 18, 2004, Pages 4530-4537

  El Kabbani, Ossama ^a   Darmanin, Connie ^a   Oka, Mitsuru ^b   Schulze Briese, Clemens ^c   Tomizaki, Takashi ^c   Hazemann, Isabelle ^d   Mitschler, Andre ^d   Podjarny, Alberto ^d  

^a MONASH UNIVERSITY   (Australia)

^b SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

^c PAUL SCHERRER INSTITUTE   (Switzerland)

^d INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; CARBAMOYL GROUP; CITRIC ACID; CYSTEINE; FIDARESTAT; FUNCTIONAL GROUP; HISTIDINE; HOLOENZYME; IMIDE; MINALRESTAT; OXIDOREDUCTASE INHIBITOR; TRYPTOPHAN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; DRUG POTENCY; ELECTRON; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; HUMAN; HYDROGEN BOND; NONHUMAN; NUCLEOTIDE SEQUENCE; OPTICAL RESOLUTION; STEREOISOMERISM; STEREOSPECIFICITY; X RAY CRYSTALLOGRAPHY;

ALDEHYDE REDUCTASE; BINDING SITES; CITRATES; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; IMIDAZOLIDINES; MOLECULAR STRUCTURE; PROTEIN BINDING; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 4143081343     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0497794     Document Type: Article

References (33)

1. Costantino, L.; Rastelli, G.; Vianello, P.; Cignarella, G.; Barlocco, D. Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches. Med. Res. Rev. 1999, 19, 3-23.
2. Yabe-Nishimura, C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol. Rev. 1998, 50, 21-33.
3. Kintoshita, J. H.; Nishimura, C. The involvement of aldose reductase in diabetic complications. Diabetes Metab. Res. 1988, 4, 323-337.
4. Dunlop, M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int. Suppl. 2000, 77, S3-S12.
5. Costantino, L.; Rastelli, G.; Gamberini, M. C.; Barlocco, D. Pharmacological approaches to the treatment of diabetic complications. Exp. Opin. Ther. Pat. 2000, 10, 1245-1262.
6. Kaul, C. L.; Ramarao, P. The role of aldose reductase inhibitors in diabetic complications: recent trends. Methods Find. Exp. Clin. Pharmacol. 2001, 23, 465-475.
7. Miyamoto, S. Recent advances in aldose reductase inhibitors: potential agents for the treatment of diabetic complications. Expert Opin. Ther. Pat. 2002, 12, 621-631.
8. Oates, P. J.; Mylari, B. L. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Exp. Opin. Invest. Drugs 1999, 8, 1-25.
9. Pfeifer, M. A.; Schumer, M. P.; Gelber D. A. Aldose reductase inhibitors: the end of an era or the need for different trial design. Diabetes 1997, 46, S82-S89.
10. El-Kabbani, O.; Darmanin, C.; Schneider, T. R.; Hazemann, I.; Ruiz, F.; Oka, M.; Joachimiak, A.; Schulze-Briese, C.; Tomizaki, T.; Mitschler, A.; Podjarny, A. Ulta-high-resolution drug design II: Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat; implications for the binding of cyclic imide inhibitors. Proteins 2004, 55, 805-813.
11. Rastelli, G.; Ferrari, A. M.; Costantino, L.; Gamverini, M. C. Discovery of new inhibitors of aldose reductase from molecular docking and database screening. Bioorg. Med. Chem. 2002, 10, 1437-1450.
12. El-Kabbani, O.; Wilson, D.; Petrash, J. M.; Quiocho, F. A. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites. Mol. Vision 1998, 4, 19-25.
13. Urzhumtsev, A.; Tête-Favier, F.; Mitschler, A.; Barbanton, J.; Barth, P.; Urzhumtseva, J. F.; Biellmann, A. D.; Podjarny, A.; Moras, D. A. 'Specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure 1997, 5, 601-612.
14. Oka, M.; Matsumoto, Y.; Sugiyama, S.; Tsuruta, N.; Matsushima, M. A potent aldose reductase inhibitor, (2S,4S)-6-Fluoro-2′, 5′dioxyspiro[chroman-4,4′-imidazoline]-2-carboxamide (Fidarestat): its absolute configuration and interaction with aldose reductase by X-ray crystallography. J. Med. Chem. 2000, 43, 2479-2483.
15. Jez, J. M.; Bennett, M. J.; Schlegel, B. P.; Lewis, M.; Penning, T. M. Comparative anatomy of the aldo-keto reductase superfamily. Biochem. J. 1997, 326, 625-636.
16. Warren, J. C.; Murdock, G. L.; Ma, Y.; Goodman, S. R.; Zimmer, W. E. Molecular cloning of testicular 20 alpha-hydroxysteriod dehydrogenase: identity with aldose reductase. Biochemistry 1993, 32, 1401-1406.
17. Tanimoto, T.; Nishijama, C. Molecular biology of aldose reductase. Exp. Med. 1991, 9, 541-547.
18. Feather, M. S.; Flynn, T. G.; Munro, K. A.; Kubiseski, T. J.; Walton, D. J. Catalysis of reduction of carbohydrate 2-oxoaldehydes (osones) by mammalian aldose reductase and aldehyde reductase. Biochim. Biophys. Acta 1995, 1244, 10-16.
19. Ratliff, D. M.; Van der Jagt, D. J.; Eaton, R. P.; Van der Jagt, D. L. Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II-a clinical research center study. J. Clin. Endocrinol. Metab. 1996, 81, 488-492.
20. El-Kabbani, O.; Old, S. E.; Ginell, S. L.; Carper, D. A. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites. Mol. Vision 1999, 5, 20-26.
21. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.
22. Ramachandran, G. N.; Sasisekharan, V. Conformation of proteins and polypeptides. Adv. Protein Chem. 1968, 23, 283-437.
23. Yamaguchi, T.; Miura, K.; Usui, T.; Unno, R.; Matsumoto, Y.; Fukushima, M.; Mizuno, K.; Kondo, Y.; Baba, Y.; Kurono, M. Synthesis and aldose reductase inhibitory activity of 2-substituted-6-fluora-2,3-dihydrospiro [4H-1-benzopyran-4,4′-imidazolidine]-2′, 5′-diones. Arzneim.-Forsch. /Drug Res. 1994, 44, 344-348.
24. Chung, S.; La Mendola, J. Cloning and sequence determination of human placental aldose reductase gene. J. Biol. Chem. 1989, 264, 4775-14777.
25. Matthews, B. W. Solvent content of protein crystals. J. Mol. Biol. 1968, 33, 491-497.
26. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276, 307-326.
27. Brünger, A. T.; Krukowski, A.; Erickson, J. W. Slow-cooling protocols for crystallographic refinement by simulated annealing. Acta Crystallogr. A 1990, 46, 585-593.
28. Sheldrick, G.; Schneider, T. SHELXL: high-resolution refinement. Methods Enzymol. 1997, 277, 319-343.
29. Roussel, A.; Cambillau, C. TURBO-FRODO molecular graphics program. In Silicon Graphics Geometry Partner Directory; Silicon Graphics: Mountain View, CA, 1989, pp 77-78.
30. McRee, D. E. XtalView/Xfit - A versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 1999, 125, 156-165.
31. Darmanin, C.; El-Kabbani, O. Modelling studies of the active site of human sorbitol dehydrogenase: an approach to structure-based inhibitor design of the enzyme. Bioorg. Med. Chem. Lett. 2001, 11, 3133-3136.
32. Darmanin, C.; El-Kabbani, O. Modelling studies on the binding of substrate and inhibitor to the active site of human sorbitol dehydrogenase. Bioorg. Med. Chem. Lett. 2000, 10, 1101-1104.
33. Kraulis, P. J. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 1991, 24, 946-950.